Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Sells $23,317.00 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 3,331 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.00, for a total value of $23,317.00. Following the sale, the chief executive officer now directly owns 74,123 shares of the company’s stock, valued at $518,861. This represents a 4.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Atara Biotherapeutics Price Performance

Shares of ATRA stock opened at $6.90 on Friday. The stock has a market cap of $39.74 million, a PE ratio of -0.27 and a beta of 0.46. The stock has a 50-day moving average of $9.85 and a 200-day moving average of $9.71. Atara Biotherapeutics, Inc. has a one year low of $5.40 and a one year high of $20.81.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.82) by $2.63. The business had revenue of $32.75 million during the quarter, compared to analyst estimates of $20.58 million. As a group, research analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at approximately $48,000. Northern Trust Corp acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at approximately $149,000. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics in the 4th quarter valued at approximately $169,000. Birchview Capital LP bought a new stake in shares of Atara Biotherapeutics during the 4th quarter worth approximately $293,000. Finally, State Street Corp raised its stake in shares of Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Canaccord Genuity Group dropped their price objective on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, January 17th. RODMAN&RENSHAW cut Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They set a “buy” rating and a $25.00 price objective for the company. Finally, TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.